Literature DB >> 8428224

Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome.

N J Lindsey1, R A Dawson, F I Henderson, M Greaves, P Hughes.   

Abstract

The level of von Willebrand factor antigen (vWF) released by endothelial cells in response to IgG isolated from 18 patients with systemic lupus erythematosus (SLE), eight patients with the anti-phospholipid syndrome (APS) and 22 controls has been measured. Incubation with IgG from the combined patient group resulted in a significantly greater release of vWF (mean stimulation index +/- SEM, 4.57 +/- 0.78) when compared with controls (1.96 +/- 0.22, P = 0.003). Furthermore, IgG from 17 patients who had had a history of thrombosis induced higher levels of vWF release (5.33 +/- 1.09) when compared with the controls (P = 0.008). These findings suggest that IgG from patients with SLE or APS is capable of stimulating vWF release and that this ability may be implicated in the thrombotic events that are observed in these conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428224     DOI: 10.1093/rheumatology/32.2.123

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  13 in total

Review 1.  Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis.

Authors:  José Delgado Alves; Bruno Grima
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis.

Authors:  A Bordron; M Dueymes; Y Levy; C Jamin; J P Leroy; J C Piette; Y Shoenfeld; P Y Youinou
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.

Authors:  C J Frijns; R H Derksen; P G De Groot; A Algra; R Fijnheer
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 4.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge.

Authors:  Irene Em Bultink
Journal:  Arthritis Res Ther       Date:  2010-02-22       Impact factor: 5.156

7.  Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies.

Authors:  K N Lai; J C Leung; K B Lai; F M Lai; K C Wong
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

8.  Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS).

Authors:  M B Hill; J L Phipps; R G Malia; M Greaves; P Hughes
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

9.  Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations.

Authors:  T M Chan; P M Yu; K L Tsang; I K Cheng
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

10.  Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.

Authors:  Johanna Gustafsson; Iva Gunnarsson; Ola Börjesson; Susanne Pettersson; Sonia Möller; Guo-Zhong Fei; Kerstin Elvin; Julia F Simard; Lars-Olof Hansson; Ingrid E Lundberg; Anders Larsson; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2009-12-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.